No exit and the organization of voice in biotechnology and pharmaceuticals

Journal of Health Politics, Policy and Law

Volumn 28, Issue 2-3, 2003, Pages 473-507

  Light, Donald W ^a   Castellblanch, Ramón ^b   Arredondo, Pablo ^c   Socolar, Deborah ^d  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b SAN FRANCISCO STATE UNIVERSITY   (United States)

^c STANFORD LAW SCHOOL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CONFERENCE PAPER; CONSUMER; COOPERATION; COST CONTROL; DRUG COST; DRUG INDUSTRY; GOVERNMENT; IDEOLOGY; LEADERSHIP; MARKET; ORGANIZATION; POLICY; POLITICS; PRESCRIPTION; PUBLIC OPINION; RESEARCH; SOCIAL SUPPORT; SOCIETY; THEORETICAL MODEL;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION; HEALTH CARE AND PUBLIC HEALTH;

BIOTECHNOLOGY; CONSUMER ORGANIZATIONS; CONSUMER PARTICIPATION; DRUG COSTS; DRUG INDUSTRY; HEALTH CARE SECTOR; HEALTH POLICY; HUMANS; LEADERSHIP; ORGANIZATIONAL CASE STUDIES; PLANTS, GENETICALLY MODIFIED; POLICY MAKING; POLITICS; POWER (PSYCHOLOGY); UNITED STATES;

EID: 0037501285     PISSN: 03616878     EISSN: None     Source Type: Journal    
DOI: 10.1215/03616878-28-2-3-473     Document Type: Conference Paper

References (100)

1. Achman, Lori, and Marsha Gold. 2002. Medicare+Choice, 1999-2001: An Analysis of Managed Care Plan Withdrawals and Trends in Benefits and Premiums. New York: Commonwealth Fund.
2. Allen, Thomas H. 1998. Prescription Drug Pricing in the First Congressional District in Maine: An International Price Comparison. Minority Staff Report, Committee on Government Reform and Oversight, U.S. House of Representatives, Washington, DC.
3. Alpha Center. 1997. The Power of Choice in the Health Care Marketplace and Its Consequences. Conference proceedings. 19 November, Washington, DC: Alpha Center.
4. Anderson, Luke. 1999. Genetic Engineering, Food, and Our Environment. White River Junction, VT: Chelsea Green.
5. Appleby, Julie. 2002. Lilly Offers Prescription Drug Card to Lure Innocent Seniors. USA Today, 5 March.
6. Banville, Beurmond. 2000. County Forums Address Drug Costs. Bangor (Maine) Daily News, 21 February, B2.
7. Barboza, David. 1999. Two Sides Square Off on Genetically Altered Food. New York Times, 18 November, A30.
8. Brasher, Philip. 2000. Better Study Is Urged on Biotech Crops' Effects. Washington Post, 18 February, A2
9. Brubaker, Bill. 2002. Is the Right Price in the Cards? Washington Post, 10 March, H1.
10. Burstein, Paul. 1998. Interest Organizations, Political Parties, and the Study of Democratic Politics. In Social Movements and American Political Institutions, ed. Anne N. Costain and Andrew S. McFarland. Lanham, MD: Rowman and Littlefield.
11. Burton, Thomas M. 2002. Pushing Pills: Reining in Drug Advertising - Backlash Is Brewing. Wall Street Journal, 13 March.
12. Carter, Janelle. 2000. Senate OK's Prescription Imports. Associated Press, 19 July.
13. Castellblanch, Ramón. 2003. Challenging Pharmaceutical Industry Political Power in Maine and Vermont. Journal of Health Politics, Policy and Law 28:109-132.
14. Cauchi, Richard. 2000. Prescription Drug Discount, Rebate, Price Control, and Bulk Purchasing Legislation. Denver, CO: National Conference of State Legislatures.
15. Cauchi, Richard, and Karmen Hanson. 2002. 2002 Prescription Drug Discount, Bulk Purchasing, and Price-Related Legislation. Denver, CO: National Conference of State Legislators.
16. Cauthan, Nancy, and Edwin Amenta. 1996. Not for Widows Only: Institutional Politics and the Formative Years of Aid to Dependent Children. American Sociological Review 61:427-448.
17. Concannon, K. 2000. Implementation of Maine Rx Program. Paper presented at the June 2000 Meeting of the Northeast Legislative Association on Prescription Drug Prices, South Portland, ME.
18. Craig, Tim. 2002. Community Leaders Decry Lobby Firm's Fax: Apparent Support of Prescription Plan Really a Move by Foes. Baltimore Sun, 9 March, A1.
19. Environmental Defense Fund (EDF). 1999. Petition, Submitted to Administrator, U.S. EPA, 13 July. Available on-line at www.environmentaldefense.org/documents/1239_Petition.
20. Freyne, Peter 2000. Money's the Best Medicine. Seven Days (Burlington, VT), 24 May.
21. Fulmer, Melinda. 2000. EPA, FDA, to Review Data before Deciding on Taco-Shell Recall. Los Angeles Times, 19 September, C1.
22. Gerth, Jeff, and Sheryl Gay Stolberg. 2000. Medicine Merchants Cultivating Alliances: With Quiet, Unseen Ties, Drug Makers Sway Debate. New York Times, 5 October.
23. Goldberg, Carey. 1999. New England Lawmakers Consider Drug Strategies. New York Times, 17 December, A22.
24. Hartley, Heather. 2003. "Big Pharma" in our Bedrooms: An Analysis of the Medicalization of Women's Sexual Problems. Advances in Gender Research 7.
25. Hirschman, Albert O. 1970. Exit, Voice, and Loyalty: Responses to Decline in Firms, Organizations, and States. Cambridge: Harvard University Press.
26. -. 1986. Rival View of Market Society and Other Recent Essays. Cambridge: Harvard University Press.
27. Horwitz, Allan. 2001. Creating Mental Illness. Chicago: University of Chicago Press.
28. Hosler, Karen. 2000. Drug-Cost Ire Gives Industry a Chill. Baltimore Sun, 4 June, A1.
29. Hunt, Michie I. 2000. Prescription Drugs and Intellectual Property Protection Report. Washington, DC: National Institute for Health Care Management.
30. Kaiser Family Foundation. 2000. The Public and Prescription Drugs. Public Opinion Update, No. 3060. September. Menlo Park, CA, and Washington, DC: Kaiser Family Foundation.
31. -. 2002a. Medicare and Prescription Drugs: A Chartpack. June.
32. -. 2002b. Roundup on State Medicaid Prescription Drug Plans. Kaiser Daily Health Policy Report, 12 March.
33. Kreiter, Marcella S. 2000. StarLink Com Scandal Continues to Spread. United Press International, 25 October.
34. Laschober, Mary A., Michelle Kitchman, Patricia Neuman, and Allison A. Strabic. 2002. Web Exclusive: Trends in Medicare Supplemental Insurance and Prescription Drug Coverage, 1996-1999. Health Affairs, 27 February. Available on-line at www.healthaffairs.org/Library/v21n2/s4.pdf.
35. Light, Donald W. 1999. Commentary: The New Paternalism. Medical Care Research and Review 56(suppl. 1):141-144.
36. -. 2000. The Sociological Character of Markets in Health Care. In Handbook of Social Studies in Health and Medicine, ed. G. Albrecht, R. Fitzpatrick, and S. C. Srimshaw. London: Sage.
37. -. 2001. Health Care Markets: Theory and Practice. In International Encyclopedia of the Social and Behavioural Sciences. Vol. 10:6523-6527. Oxford: Elsevier.
38. Lofland, John. 1985. Protest: Studies of Collective Behavior and Social Movements. New Brunswick, NJ: Transaction Books.
39. -. 1996. Social Movement Organizations: Guide to Research on Insurgent Realities. New York: Aldine de Gruyter.
40. Lohr, Steve. 2002. New Economy: The Intellectual Property Debate Takes a Page from Nineteenth-Century America. New York Times, 14 October, C4.
41. Losey, John E., et al. 1999. Transgenic Pollen Harms Monarch Larvae. Nature 399:214.
42. Mace, David. 2002. Home Remedy: How Tiny Vermont Is Leading an Effort to Reduce Prescription Drug Costs. Rutland Herald, 13 January. Available on-line at rutlandherald.nybor.con/Archive/Article/40580.
43. Mann, Michael. 2001. Brussels Firm on Plans for Biotech Food. London Financial Times, 28 August, 9.
44. Market Decisions. 2000. Poll on Drug Price Policy. Portland Maine Times. 15 April.
45. Marks, P. 2000. Costly Prescriptions: One Issue That Fits All. New York Times, 22 October, 1.
46. Maxwell, Stephanie, Marilyn Moon, and Misha Segal. 2001. Growth in Medicare and Out-of-Pocket Spending: Impact on Vulnerable Beneficiaries. New York: Commonwealth Fund.
47. McAdam, Doug, John D. McCarthy, and Mayer M. Zald. 1996. Comparative Perspectives on Social Movements. Cambridge: Cambridge University Press.
48. McChesney, Robert W. 1999a. The New Global Media: It's a Small World of Big Conglomerates. The Nation. 29 November.
49. -. 1999b. Rich Media, Poor Democracy. Champaign: University of Illinois Press.
50. McHughen, Alan. 2000. Pandora's Picnic Basket. New York: Oxford University Press.
51. McLaughlin, Catherine G. 1999. Health Care Consumers: Choices and Constraints. Medical Care Research and Review 56(suppl. 1):24-59.
52. Mechanic, David. 1996. Changing Medical Organization and the Erosion of Trust. Milbank Quarterly 74:171-189.
53. -. 1997. Managed Care As a Target of Distrust. Journal of the American Medical Association 177:1810-1820.
54. -. 2000. Managed Care and the Imperative for a New Professional Ethic. Health Affairs 19(5):100-111.
55. Mechanic, David, and Mark Schlesinger. 1996. The Impact of Managed Care on Patients' Trust in Medical Care and their Physicians. Journal of the American Medical Association 275:1693-1697.
56. Moore, Michael O'D. 2000. State to Oversee Price of Drugs. Bangor (Maine) Daily News, 12 May.
57. Morone, James A. 1990. The Democratic Wish. New York: Basic Books.
58. Nathanson, Constance A. 1996. Disease Prevention As Social Change: Toward a Theory of Public Health. Population and Development Review 22:609-637.
59. -. 1999. Social Movements As Catalysts for Policy Change: The Case of Smoking and Guns. Journal of Health Politics, Policy and Law 24:421-488.
60. National Institute for Health Care Management Foundation (NIHCM). 2002. Prescription Drug Expenditures in 2001: Another Year of Escalating Costs. Washington, DC: NICHM.
61. O'Donnell, Guillermo. 1975. Reflexiones sobre las tendencias generales de cambio en el estado burocrático-autoritario. Buenos Aires: CEDES.
62. Orbeton, Jane 2000. Public Law 786: An Act to Establish Fairer Pricing for Prescription Drugs. Augusta: Maine State Legislature Office of Policy and Legal Services.
63. Ostlie, Ken, W. D. Hutchinson, and R. L. Hellmich. 1997. Bt Corn & European Corn Borer: Long-term Success through Resistance Management. Minneapolis: University of Minnesota.
64. Otis, Anthony 1999. Lobbyist Information. Montpelier: Vermont Secretary of State.
65. Peterson, Mark A., ed. 1999. The Managed Care Backlash. Special issue of Journal of Health Politics, Policy and Law 42:873-1218.
66. Pew Charitable Trusts. 2002. Pharming the Field: A Look at the Risks and Benefits of Bioengineering Plants to Produce Pharmaceuticals. Washington, DC, 17-18 July. Quotation available on the Pew Charitable Trusts Web site at pewagbiotech.org/events/0717/index.php#agenda.
67. Pharmacy Defense Fund Newsletter. 2000. Fall/Winter. San Rafael, CA.
68. Pingree, Chellie. 2001. Interview by Ramón Castellblanch on enactment of LD 2599, 26 March.
69. Pollack, Andrew. 2000. European Company Will Buy Entire Crop of Corn in Recall. New York Times, 30 September, 14.
70. -. 2001. Data on Genetically Modified Corn. New York Times, 8 September, C2.
71. Prescription Access Litigation Project (PAL). 2001. Consumer Groups Charge Industrywide Price Manipulation - Over $800 Million in Illegal Profits from Medicare and Medicaid Patients. PAL press release, Boston. 20 December.
72. -. 2003. Information available on PAL Web site at www.prescriptionaccesslitigation.org.
73. Protulis, Steve. 1999. 60 Minutes Report. Silver Spring, MD: National Council of Senior Citizens.
74. Rauch, Jonathan. 1994. The Hyperpluralism Trap. New Republic, 6 June, 22-25.
75. Rifkin, Jeremy. 1999. Unknown Risks of Genetically Engineered Crops. Boston Globe, 7 June, A13.
76. Rodwin, Marc A. 2000. Promoting Accountable Managed Health Care: The Potential Role for Consumer Voice. Indianapolis: Center for Law and Health, Indiana University Law School.
77. -. 2001. Consumer Voice and Representation in Managed Healthcare. Journal of Health Law 34:223-272.
78. Rosenthal, Marsha, and Mark Schlesinger. 2002. Not Afraid to Blame: The Neglected Role of Blame Attribution in Medical Consumerism and Some Implications for Health Policy. Milbank Quarterly 80:41-95.
79. Rowland, Diane. 2001. Prescription Drug Coverage for the Medicare Population. Washington, DC: Kaiser Commission on Medicaid and the Uninsured.
80. Sager, Alan. 2001. Americans Would Save $38 Billion in 2001 if We Paid Canadian Prices for Brand Name Prescription Drugs. Testimony to Subcommittee on Consumer Affairs, Foreign Commerce, and Tourism of the United States Senate Committee on Commerce, Science, and Transportation. 5 September. Available on-line at commerce.senate.gov/hearings/090501Saner.pdf.
81. Sager, Alan, and Deborah Socolar. 1999. Affordable Medications for Americans. Report presented to U.S. House of Representatives Prescription Drug Task Force. Access and Affordability Monitoring Project, Boston University School of Public Health. 27 July. Available on-line at www.house.gov/berry/taskforcestudies.shtml.
82. -. 2000. A Prescription Drug Peace Treaty - Cutting Prices to Make Prescription Drugs Affordable for All and to Protect Research - State-by-State Savings. Health Reform Program, Boston University School of Public Health. 27 July. Available on-line at www.healthreformprogram.org.
83. Sanders, Bernard. 2000. Reasonable Pricing for Prescription Drugs Amendment Passes. Press release issued 14 June by the office of Bernard Sanders, U.S. House of Representatives, Washington, DC.
84. Schlesinger, Mark, Benjamin Druss, and Tracey Thomas. 1999. No Exit? The Effect of Health Status on Dissatisfaction and Disenrollment from Health Plans. Health Services Research 34:547-576.
85. Sipress, Alan, and Marc Kaufman. 2001. U.S. Challenges EU's Biotech Food Standards. Washington Post, 26 August, A1.
86. Smelser, Neil J. 1963. Theory of Collective Action. New York: Free Press.
87. Sneyd, Ross. 2000. "Lobbyists Work Overtime on Drug Issue. Associated Press, 16 May.
88. Snow, David A., E. B. Rochford, Steven K. Worden, and Robert D. Benford. 1986. Frame Alignment Process, Micromobilization, and Movement Participation. American Sociological Review 51:464-481.
89. Stuart, Bruce, Dennis Shea, and Becky A. Briesacher. 2000. Prescription Drug Costs for Medicare Beneficiaries: Coverage and Health Status Matters. New York: Commonwealth Fund.
90. Swedberg, Richard. 1998. Markets As Social Structures. In The Handbook of Economic Sociology, ed. Neil J. Smelser and Richard Swedberg. Princeton, NJ: Princeton University Press.
91. United Auto Workers. 2000. Rx Express. Solidarity, June. Available on-line at www.uaw.org/solidarity/00/0600/feature03.html.
92. U.S. Department of Agriculture (USDA). 1999. Objective Yield Survey. October. Washington, DC: National Agriculture Statistics Service.
93. U.S. Department of Health and Human Services (DHHS). 2000. Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices. April. Washington, DC: DHHS.
94. Washuk, Bonnie. 2000. Bill's Aim: Controlling Drug Prices. Lewiston (Maine) Sun Journal, 27 January.
95. -. 2002. Attorney General Confident of Victory over Drug Companies. Lewiston (Maine) Sun Journal, 3 October.
96. Weinstein, J. 2001. Court Upholds Maine Rx Program. Portland Press Herald.
97. Weiss, Rick. 1999. Biotech vs. "Bambi" of Insects? Gene-Altered Corn May Kill Monarch. Washington Post, 20 May, A3.
98. Wilson, Steve. 1999. Biotechnology Critics Overstate Case. Arizona Republic, 21 November.
99. Wraight, C. L., et al. 2000. Absence of Toxicity of Bacillus Thuringiensis Pollen to Black Swallowtails under Field Conditions. Proceedings of the National Academy of Science 97(14):7700-7703.
100. Yoon, Carol Kaisuk. 1999. Altered Com May Imperil Butterfly, Researchers Say. New York Times, 20 May, A1.